Showing results (21-30 of 29) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
The Oncologist|June 28, 2017
Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 InhibitorsJulia Judd, Matthew Zibelman, Elizabeth Handorf, et al.Journal for Immunotherapy of Cancer|March 3, 2021
Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind studyNiannian Ji, Neelam Mukherjee, Ryan M Reyes, et al.The Journal of Urology|June 28, 2022
A Decade of Robotic-Assisted Radical Nephrectomy with Inferior Vena Cava Thrombectomy: A Systematic Review and Meta-Analysis of Perioperative OutcomesHarshit Garg, Sarah P Psutka, Abraham Ari Hakimi, et al.JCO Oncology Practice|May 11, 2022
Disparities in Cancer Genetic Testing and Variants of Uncertain Significance in the Hispanic Population of South TexasStephanie Soewito, Rachel Wyatt, Emily Berenson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2024
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor TherapyDaniel P Petrylak, Scott T Tagawa, Rohit K Jain, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2024
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3Petros Grivas, Damien Pouessel, Chandler H Park, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With PembrolizumabMatthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, et al.The New England Journal of Medicine|February 18, 2026
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder CancerChristof Vulsteke, Nabil Adra, Pongwut Danchaivijitr, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial CancerPeter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, et al.Pageof 3